ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer
Status:
Suspended
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a study of ARQ-761 (beta-lapachone) with gemcitabine/nab-paclitaxel chemotherapy in
subjects with advanced (metastatic, unresectable, or recurrent) pancreatic cancer that has
not been treated with gemcitabine.